[ADDT Membership Roster] [ADDT Meeting Rosters]

The AIDS Discovery and Development of Therapeutics [ADDT] Study Section reviews applications on the design, discovery, and development of therapeutics for HIV and AIDS-related diseases.  Proposed agents that inhibit the viral lifecycle may include conventional pharmacotherapies, natural products, gene-based strategies, and microbicides. Specific areas covered by ADDT are:

• Development of targeted screens for new inhibitors of HIV/AIDS.
• Identification and characterization of natural products for prevention or therapy of HIV/AIDS.
• Pre-clinical development of drugs, formulations, and delivery vehicles for HIV/AIDS therapy.
• Design and development of gene-based therapies and vectors for HIV/AIDS.
• Mechanisms of drug action and viral drug resistance.
• Pharmacology of drugs and formulations for HIV/AIDS.
• Discovery and development of microbicides to prevent HIV transmission.
• Computational modeling and structure-assisted design of anti-HIV/AIDS agents.
• Animal and tissue models for assessing delivery and efficacy of anti HIV/AIDS therapies.

The study sections with most closely related areas of similar science listed in rank order are:

AIDS Molecular and Cellular Biology (AMCB)
AIDS-associated Opportunistic Infections and Cancer (AOIC)
HIV/AIDS Vaccines Study Section (VACC)
AIDS Immunology and Pathogenesis (AIP)
AIDS Clinical Studies and Epidemiology (ACE)